Shanghai Pharmaceutical (Group) Co., Ltd. is one of the oldest and largest pharmaceutical enterprises in China. Its capital structure is that China Huayuan Group holds 40%, Shanghai Huayi Group and Shanghai Industrial Investment Company hold 30%. In recent years, Shanghai Pharmaceutical (Group) Co., Ltd. has maintained a strong momentum of 8% annual sales growth rate and formed a leading edge in production, sales and research and development in various fields of medicine. The goal of Shanghai Pharmaceutical (Group) Co., Ltd. is to build the "aircraft carrier" of China Pharmaceutical.
The API Division is one of the four divisions of Shanghai Pharmaceutical (Group) Co., Ltd., and its existing resources include Huaihai Pharmaceutical Factory, Jiangqiao Pharmaceutical Factory, Shanghai Sanwei Pharmaceutical Co., Ltd., Shanghai Hualian Pharmaceutical Co., Ltd. and Shanghai Wuzhou Pharmaceutical Co., Ltd.
With strong scientific and technological strength, complete equipment and facilities, strict management, rigorous production and low cost, the API Division of Shanghai Pharmaceutical Group can provide customers with a variety of products that meet GMP production requirements and produce APIs in many fields, including antipyretic and analgesic drugs, central nervous system, vitamins, respiratory system, antibiotics, diabetes treatment, gastrointestinal disease treatment, antiallergic, antitumor, cardiovascular and mental diseases. Many varieties have passed the certification and registration of FDA, TGA, COS and other certification bodies, with customers all over Europe, America, Southeast Asia and other places, and have good cooperation with famous multinational companies including Schering, Nike, Roche and so on. The API Division has a wide range of chemical reaction capabilities and even some special capabilities, with technical characteristics such as polypeptide synthesis, chiral synthesis, purification and fluorination, and a considerable proportion of its products are exclusively produced in China. The API Division has a Spark API base with vast space and complete supporting facilities as a cooperation platform, which provides a strong guarantee for future contract production and order manufacturing in terms of technology and capacity. The API Division will establish and constantly improve its overseas marketing network, communicate directly with target customers and provide customers with various services in a timely manner.
Shanghai Pharmaceutical Group Co., Ltd. (hereinafter referred to as the company) was established by Shanghai Pharmaceutical (Group) Co., Ltd. to replace all the assets of Shanghai No.4 Pharmaceutical Co., Ltd. with the high-quality assets of its wholly-owned subsidiaries, Shanghai Pharmaceutical Industry Sales Co., Ltd. and Shanghai Tian Ping Pharmaceutical Factory, and resumed listing on September 9, 20 1998. On April 9, 20 10, the company completed the registration formalities of company name change in Shanghai Administration for Industry and Commerce, and the company name was officially changed to "Shanghai Pharmaceutical Group Co., Ltd." from now on.